Original Article

You have full text access to this OnlineOpen article

Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis

  1. Rafael Bañares1,
  2. Eduardo Moitinho2,
  3. Ana Matilla1,
  4. Juan Carlos García-Pagán2,
  5. José Luis Lampreave1,
  6. Carlos Piera2,
  7. Juan G. Abraldes2,
  8. Alejandro De Diego1,
  9. Agustín Albillos3,
  10. Jaime Bosch M.D.2,*

Article first published online: 7 MAR 2007

DOI: 10.1002/hep.1840360612

Issue

Hepatology

Hepatology

Volume 36, Issue 6, pages 1367–1373, December 2002

Additional Information

How to Cite

Bañares, R., Moitinho, E., Matilla, A., García-Pagán, J. C., Lampreave, J. L., Piera, C., Abraldes, J. G., De Diego, A., Albillos, A. and Bosch, J. (2002), Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology, 36: 1367–1373. doi: 10.1002/hep.1840360612

Author Information

  1. 1

    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, Spain

  2. 2

    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain

  3. 3

    Hepatic Hemodynamic Laboratory, Gastroenterology Department, Hospital Ramón y Cajal, Universidad de Alcalá de Henares, Madrid, Spain

*Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain. fax: (34) 932279856

Publication History

  1. Issue published online: 7 MAR 2007
  2. Article first published online: 7 MAR 2007
  3. Manuscript Accepted: 7 SEP 2002
  4. Manuscript Received: 23 APR 2002

Funded by

  • Fondo de Investigacines Sanitarias. Grant Numbers: 95/418, 00/444

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (750K)

Reference

  • 1
    Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, Alberts J, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990; 99: 1401–1407.
  • 2
    Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, Rodes J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056–1059.
  • 3
    Escorsell A, Bordas JM, Castaneda B, Llach J, Garcia-Pagan JC, Rodes J, Bosch J. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000; 31: 1061–1067.
    Direct Link:
  • 4
    Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, Gatta A. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinic effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 32: 930–934.
    Direct Link:
  • 5
    Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, Cusso X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334: 1624–1629.
  • 6
    Villanueva C, Minana J, Ortiz J, Gallego A, Soriano G, Torras X, Sainz S, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345: 647–655.
  • 7
    Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 1991; 324: 1532–1538.
  • 8
    D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332–354.
    Direct Link:
  • 9
    Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997; 25: 63–70.
    Direct Link:
  • 10
    Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991; 114: 869–873.
  • 11
    Merkel C, Sacerdoti D, Bolognesi M, Enzo E, Marin R, Bombonato G, Angeli P, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. Hepatology 1997; 26: 34–39.
  • 12
    Albillos A, Garcia-Pagan JC, Iborra J, Bandi JC, Cacho G, Perez-Paramo M, Escorsell A, et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5- mononitrate in the treatment of portal hypertension. Gastroenterology 1998; 115: 116–123.
  • 13
    Albillos A, Lledo JL, Rossi I, Perez-Paramo M, Tabuenca MJ, Banares R, Iborra J, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995; 109: 1257–1265.
  • 14
    Gournay J, Masliah C, Martin T, Perrin D, Galmiche JP. Isosorbide mononitrate and propranolol compared with propranololalone for the prevention of variceal rebleeding. Hepatology 2000; 31: 1239–1245.
    Direct Link:
  • 15
    Merkel C, Marin R, Sacerdoti D, Donada C, Cavallarin G, Torboli P, Amodio P, et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 31: 324–329.
    Direct Link:
  • 16
    Forrest EH, Bouchier IA, Hayes PC. Acute haemodynamic changes after oral carvedilol, a vasodilating beta-blocker, in patients with cirrhosis. J Hepatol 1996; 25: 909–915.
  • 17
    Banares R, Moitinho E, Piqueras B, Casado M, Garcia-Pagan JC, de Diego A, Bosch J. Carvedilol, a new nonselective beta-blocker with intrinsic anti-Alpha1-adrenergic activity, has a greater portal hypertensive effect than propranolol in patients with cirrhosis. Hepatology 1999; 30: 79–83.
    Direct Link:
  • 18
    Packer M. Effects of beta-adrenergic blockade on survival of patients with chronic heart failure. Am J Cardiol 1997; 80: 46L–54L.
  • 19
    Frishman WH. Carvedilol. N Engl J Med 1998; 339: 1759–1765.
  • 20
    Salmeron JM, Ruiz dA, Gines A, Garcia-Pagan JC, Gines P, Feu F, Claria J, et al. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology 1993; 17: 800–806.
  • 21
    Gonzalez-Abraldes J, Albillos A, Banares R, del Arbol LR, Moitinho E, Rodriguez C, Gonzalez M, et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 2001; 121: 382–388.
  • 22
    Albillos A, Lledo JL, Banares R, Rossi I, Iborra J, Calleja JL, Garrido A, et al. Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. Hepatology 1994; 20: 611–617.
  • 23
    Navasa M, Chesta J, Bosch J, Rodes J. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 1989; 96: 1110–1118.
  • 24
    Groszmann RJ. Beta-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: the good, the bad, the ugly. Gastroenterology 1997; 113: 1794–1797.
  • 25
    Neugebauer G, Gabor M, Reiff K. Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction. J Cardiovasc Pharmacol 1992; 19 (Suppl 1): S142–S146.
  • 26
    Ruffolo RR, Jr., Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990; 38 (Suppl 2): S82–S88.
  • 27
    Morillas RM, Planas R, Cabre E, Galan A, Quer JC, Feu F, Garcia Pagan JC, et al. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Hepatology 1994; 20: 1502–1508.
    Direct Link:
  • 28
    Rodriguez-Perez JC, Losada A, Anabitarte A, Cabrera J, Llobet J, Palop L, Plaza C. Effects of the novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablated rats. J Pharmacol Exp Ther 1997; 283: 336–344.
  • 29
    Barone FC, Nelson AH, Ohlstein EH, Willette RN, Sealey JE, Laragh JH, Campbell WG, Jr., et al. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther 1996; 279: 948–955.
  • 30
    Stanley AJ, Therapondos G, Helmy A, Hayes PC. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis. J Hepatol 1999; 30: 479–484.
  • 31
    Tripathi D, Therapondos G, Lui HF, Stanley AJ, Hayes PC. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther 2002; 16: 373–380.
    Direct Link:
Get PDF (750K)